Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

Recruitment is underway for a clinical trial testing a vaccine candidate produced with The University of Queensland's ...

In this article, we take a look at five biotech companies developing potentially transformative medicines to treat cystic ...

Since their introduction last year, researchers have been monitoring the real-world impact of the new respiratory syncytial virus (RSV) vaccines. In a recent commentary in The Lancet, Angela Branche, ...

Beyfortus is the first long-acting antibody approved in Canada for the prevention of RSV lower respiratory tract disease in newborns and infants through their first RSV season. Sanofi noted that ...

Two Hamilton-area hospitals are opening clinics this fall for babies to receive a new medicine to prevent respiratory syncytial virus (RSV). Next Monday, the clinics will open in McMaster ...

Six out of 10 infants and newborns in Canada will have access to the protective antibody Beyfortus ® for the first time this season ...

Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety profile of non-adjuvanted bivalent RSV vaccine candidate (SCB-1019)-- -- RSV neutralizing antibodies for ...

Since their introduction last year, researchers have been monitoring the real-world impact of the new respiratory syncytial virus (RSV) vaccines. In a recent commentary in The Lancet, Angela ...

Yes, although it is very rare, it is possible for respiratory syncytial virus (RSV) to cause meningitis. Specifically, it can cause viral meningitis. Viral meningitis is the most common type of ...

Ultimately, the goal is to develop a shot that combines seasonal flu, COVID-19 and respiratory syncytial virus (RSV) protection with a single vaccine, said the biotech. It is also looking at ...